Skip to main content
Smart Investors Daily
GM

NYSE · GMAB

Genmab A/S

Healthcare · Biotechnology

$50.97

Up+$0.38 (+0.75%)

Updated Nov 20, 2026, 1:45 AM

SID Score

8.1/10

Composite research score

Smart Money

60/100

Neutral

Market cap
19.89B
P/E ratio
14.56
Dividend yield
0.00%
52-week range
$23.62 – $59.97
Volume
2.96M
Avg. volume
2.09M

Price performance · GMAB

GMAB price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

GMAB closed at $50.97 after 20 trading sessions, up 27.42% for the selected period.

Last close
$50.97
Period change
+27.42%
Period low
$40.00
Period high
$57.29
Daily close
View OHLC price history
GMAB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$51.60$52.26$50.89$50.972.96M
Nov 17, 2026$50.90$52.08$50.86$51.963.32M
Nov 16, 2026$52.615$52.82$51.51$51.572.43M
Nov 13, 2026$51.22$51.615$50.68$51.373.73M
Nov 12, 2026$52.20$53.03$51.535$51.745.63M
Nov 11, 2026$52.89$54.09$52.32$53.873.92M
Nov 10, 2026$54.87$55.23$53.15$54.073.09M
Nov 9, 2026$54.36$55.91$53.315$55.805.14M
Nov 6, 2026$52.36$54.15$51.2243$53.637.83M
Nov 5, 2026$55.07$55.27$52.6201$52.744.4M
Nov 4, 2026$56.01$56.20$53.76$55.124.3M
Nov 3, 2026$55.46$56.50$55.10$55.523.06M
Nov 2, 2026$56.21$56.84$54.645$54.924.42M
Oct 30, 2026$57.40$59.0228$56.53$57.068.65M
Oct 29, 2026$56.56$58.19$55.68$56.496.25M
Oct 28, 2026$44.63$59.97$44.35$57.2929.28M
Oct 27, 2026$44.41$44.99$43.98$44.674.93M
Oct 26, 2026$44.79$45.445$44.08$44.6857.47M
Oct 23, 2026$39.84$44.34$39.635$43.7913M
Oct 22, 2026$39.675$40.165$39.50$40.004.69M

Latest GMAB news

The latest Smart Investors Daily articles mentioning GMAB.

GMAB research

Overview

Company profile and research snapshot.

Company profile

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$41.25
Implied upside
—
Analysts
—
GMAB recent ratings
DateFirmRatingTarget
Sep 23, 2026ROTHSCHILD & CO REDBURNBuy—
Sep 23, 2026JYSKE BANKBuy—
Sep 14, 2026H.C. WAINWRIGHT & CO., LLCBuy—
Aug 31, 2026BNP PARIBASOutperform—
Aug 7, 2026DNB CARNEGIEBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 13, 2026

Genmab (CPSE:GMAB) Stock Could Be 47% Undervalued As Epcoritamab Approvals Expand

Genmab has delivered a sharp rerating over the past year, and the question now is whether the current share price is properly supported by the cash flows investors can reasonably expect from the business. With the Discounted Cash Flow (DCF) intrinsic value estimate pointing squarely at those cash flows, the recent surge puts that framework under the spotlight. Over the past 12 months the stock has gained 79.7%, which puts a lot of weight on the idea that future cash generation will grow into...

Yahoo · Nov 12, 2026

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; November 12, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in

Yahoo · Nov 10, 2026

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,961 shares at DKK 1,362.5,17,676 shares at DKK 1,615,949 shares at DKK 1,948,25,635 shares at DKK 2,070,6,1

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.